^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Gastroesophageal Junction Adenocarcinoma
    Drug:cisplatin (DNA synthesis inhibitor) +
    capecitabine (Thymidylate synthase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Esophageal and Esophagogastric Junction Cancers: Preferred Regimens…Preferred Regimens…Capecitabine and cisplatin.